BeOne Medicines (ONC) Non Operating Income (2023 - 2025)
BeOne Medicines (ONC) posted quarterly Non Operating Income of $3.0 million for Q3 2025, down 71.54% year-over-year from $10.6 million in Q3 2024, and down 13.38% quarter-over-quarter from $3.5 million in Q2 2025.
BeOne Medicines (ONC) Non Operating Income (2023 - 2025) Analysis & Trends
BeOne Medicines (ONC) has reported Non Operating Income for 3 consecutive years, with $3.0 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Non Operating Income fell 71.54% year-over-year to $3.0 million; the TTM figure through Sep 2025 stood at $20.2 million (down 64.15% YoY), while the FY2024 annual figure was $47.8 million, down 35.36% from the prior year.
- Non Operating Income retreated to $3.0 million in Q3 2025 per ONC's latest filing, from $3.5 million in the prior quarter.
- Across five years, Non Operating Income topped out at $26.6 million in Q3 2023 and bottomed at $3.0 million in Q3 2025.
- Historically, Non Operating Income has averaged $11.5 million across 3 years, with a median of $10.6 million in 2024.
- Annual changes were most pronounced in 2024 — Non Operating Income sank 52.02% — and 2025, when it plunged 73.56%.
- BeOne Medicines' Non Operating Income stood at $16.3 million in 2023, then tumbled by 52.02% to $7.8 million in 2024, then tumbled by 61.21% to $3.0 million in 2025.
- Business Quant data shows ONC's Non Operating Income at $3.0 million in Q3 2025, $3.5 million in Q2 2025, and $5.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.03 Mn |
| Jun 30, 2025 | 3.50 Mn |
| Mar 31, 2025 | 5.85 Mn |
| Dec 31, 2024 | 7.81 Mn |
| Sep 30, 2024 | 10.64 Mn |
| Jun 30, 2024 | 13.23 Mn |
| Mar 31, 2024 | 16.16 Mn |
| Dec 31, 2023 | 16.27 Mn |
| Sep 30, 2023 | 26.65 Mn |